Prolonged remission of endometrial cancer with paclitaxel and carboplatin

Anti-Cancer Drugs

Volumn 9, Issue 3, 1998, Pages 283-285

  Vasuratna, Apichai ^a   Kudelka, Andrzej P ^a   Edwards, Creighton L ^a   Wootipoom, Virat ^a   Verschraegen, Claire F ^a   Charnsangavej, Chusilp ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carboplatin; Endometrial cancer; Paclitaxel; Postinduction treatment; Prolonged remission

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANTINEOPLASTIC AGENT; CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ALOPECIA; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL TRIAL; DRUG INDUCED DISEASE; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; NAUSEA; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

EID: 0031950274     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199803000-00011     Document Type: Article

References (22)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1997; 4: 5.
2. Petterson F. Annual report of the results of the treatment in gynecologic cancer. Int J Gynecol Obstet 1991; 36: 132.
3. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcino ma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984; 17: 85.
4. Podratz KC, O'Brien PC, Malkasian GD, Decker DG, Jefferies JA, Edmonson JH. Effects of progestational agents in the treatment of endometrial carcinoma. Obstet Gynecol 1985; 66: 106.
5. Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 1996; 60: 288.
6. Barakat RR, Park RC, Grigsby PW, et al. Corpus: epithelial tumors. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia. Lippincott-Raven 1997; 859.
7. Reddy RD, Kudelka AP, Gonzalez de LC, Edwards CL, Kavanagh JJ. Tumors of the uterine corpus. In: Pazdur R, ed. Medical oncology: a comprehensive review. New York: Huntington 1996: 407.
8. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal funtion. J Clin Oncol 1989; 11: 1748.
9. Trope C, Grundsell H, Johnsson J, et al. A phase II study of cisplatinum for recurrent corpus cancer. Eur J Cancer 1980; 16: 1025.
10. Seski JC, Edwards CL, Herson J, Rutledge FN. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 1982; 59: 225.
11. Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1989; 33: 68.
12. Burke TW, Munkarah A, Kavanagh JJ, et al. Treatment of advanced or recurrent endometrial carcinoma with singleagent carboplatin. Gynecol Oncol 1993; 51: 397.
13. Long HJ, Pfeifle DM, Wieand HS, Krook JE, Edmonson JH, Buckner JC. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 1988; 80: 276.
14. Green JB, Green S, Alberts DS, O'Toole R, Surwit EA. Noltimier JW. Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 1990; 75: 696.
15. Horton J, Begg CB, Arseneault J, et al. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 1978; 65: 159.
16. Thigpen JT, Buchsbaum HJ, Mangan C, et al. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1979; 63: 21.
17. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1408.
18. Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol 1994; 21: 107.
19. Burke TW, Gershenson DM. Chemotherapy as adjuvant and salvage treatment in women with endometrial carcinoma. Clin Obstet Gynecol 1996; 39: 16.
20. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group Study. Gynecol Oncol 1996; 62: 278.
21. Lissoni A, Zanetta G, Gabriele LA, Parma G, Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996; 7: 861.
22. Woo HL, Swenerton KD, Hoskins PJ. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 1996; 19: 290.